This week on IPWatchdog Unleashed, I spoke with Emily Johnson, Nicholas Lanzatella, Kwame Mensah, and Corey Salsberg. This conversation took place on November 9, 2026, at IPWatchdog Studios at the fifth annual Life Sciences Masters™ conference. We examine how artificial intelligence is changing life sciences research and patent strategy. Our focus was on the emergence of super-fast followers, who are competitors positioned to quickly analyze published inventions and rapidly pursue related candidates and patent filings. For an industry built on expensive, uncertain research, the implications reach well beyond faster drafting or more efficient discovery. At stake is the balance between accelerating the development of new medicines and preserving the economic incentives that make pioneering discoveries possible in the first place.
Today, the U.S. Supreme Court denied the petition for writ of certiorari filed in Genuine Enabling Technology LLC v. Sony Group Corp., which challenged lower court rulings dismissing Genuine Enabling Technology’s (GET) patent infringement claims against Sony Playstation controllers under the doctrine of equivalents. In denying cert, the Court avoided clarifying whether a patentee’s statutory presumption under 35 U.S.C. § 112(f) to equivalents of a means-plus-function claim can be extinguished as a matter of law for failing to account for each component of the claimed structure.
On October 14, 2026, the Food and Drug Administration (FDA) announced the Rare Disease Framework Initiative. The goal of this effort is quite essential for patients with rare (orphan) diseases – to develop an approach for assessing medicines for orphan diseases with a focus on the evidence that can be gathered for this assessment. The FDA proposes to include disease characteristics, patient needs, patient population size, and characteristics of orphan medications. The initiative does not itself establish new approval standards. Although the initiative relates to regulatory evidence matters, it also raises a separate legal question about the evidence needed to support patent claim scope.
The U.S. Court of Appeals for the Federal Circuit (CAFC) issued a decision Friday in Pioneer Hi-Bred International, Inc. v. Inari Agriculture, Inc. affirming a Patent Trial and Appeal Board (PTAB) final written decision that found claims 1 through 33 of a patent on herbicide-degrading enzymes unpatentable for lack of enablement. The CAFC rejected arguments that the PTAB improperly relied on experimental data generated after the patent’s priority date and abused its discretion in crediting an expert witness.
The U.S. Court of Appeals for the Federal Circuit (CAFC) on Thursday issued a precedential decision affirming a finding of invalidity of certain claims of Satius Holding, LLC’s wireless communications patent, but holding that the district court’s reasoning, which focused on indefiniteness, was erroneous.
In 2025, a patent dispute between Chinese companies in the camera-module space drew close attention across the industry — SUNNY v. AAC [Patent Reexamination and Invalidation Department Decision No. 566288, et al.]. The case ended with 11 patents invalidated, four of them in their entirety. There was a single reason: the claims were not supported by the specification.
The U.S. Court of Appeals for the Federal Circuit (CAFC) issued a decision today reversing in part and vacating in part a series of district court rulings that had invalidated a patent covering a firearm cartridge magazine housing. Chief Judge Moore wrote for the court, joined by Circuit Judges Stoll and Stark, finding the U.S. District Court for the District of Wyoming erred by treating certain claim terms as indefinite.
The U.S. Court of Appeals for the Federal Circuit (CAFC), in a precedential decision, on Thursday affirmed a district court ruling that found certain claims of Wyeth LLC’s two patents for methods of cancer treatment invalid for lack of enablement. Wyeth sued AstraZeneca Pharmaceuticals in September 2021, alleging that AstraZeneca induced infringement of its U.S. Patents 10,603,314 and 10,596,162 “based on marketing, distribution, and sales of its irreversible EGFR inhibitor Tagrisso (osimertinib).”
The U.S. Court of Appeals for the Federal Circuit (CAFC) issued a precedential decision today in Teva Pharmaceuticals International GmbH v. Eli Lilly and Company, reversing the United States District Court for the District of Massachusetts’s grant of judgment as a matter of law (JMOL) of invalidity of Teva Pharmaceuticals International GmbH and Teva Pharmaceuticals USA, Inc.’s headache treatment patents. The district court found that the asserted claims were invalid for failing to satisfy both the written description and enablement requirements of 35 U.S.C. § 112, but the CAFC found the district court’s grant of JMOL improper on both counts. The opinion was authored by Judge Prost and joined by Judge Cunningham and District Judge Andrews.
Today, the U.S. Court of Appeals for the Federal Circuit issued a precedential ruling in Seagen Inc. v. Daiichi Sankyo Co., Ltd., reversing the Eastern District of Texas’ denial of judgment as a matter of law (JMOL) that Seagen’s patent claims lacked both written description support and enablement. Applying precedent from both the U.S. Supreme Court and the Federal Circuit’s predecessor, the Court of Customs and Patent Appeals (CCPA), the appellate court found that Seagen’s disclosure on the original patent application claiming its antibody-drug conjugate cancer treatment was too broad to give the later-filed patent-at-issue the original application’s priority date, and also required undue experimentation to discover effective drug combinations.
Growing consensus is emerging that artificial intelligence (AI) may assist biotechnology and life sciences companies to draft patents that satisfy written description and enablement requirements. The U. S. Supreme Court’s decision in Amgen Inc. v. Sanofi reiterated that patentees cannot claim a wide functional class of inventions without providing sufficient guidance or examples to enable others to use the full range of what is claimed (Amgen Inc. v. Sanofi, 598 U.S. 594 (2023)). The Supreme Court did recognize in some cases that disclosing a general property common to a class or genus of embodiments may be enough to satisfy the enablement requirement.
The U.S. Court of Appeals for the Federal Circuit (CAFC) on Wednesday issued a precedential decision in Brita LP v. International Trade Commission, affirming the International Trade Commission’s (ITC’s) finding that claims of a Brita patent for a water filtration system are invalid for lacking adequate written description and lack of enablement. The opinion was authored by Circuit Judge Prost and joined by Judges Reyna and Chen.
A number of amici weighed in last week to urge the U.S. Supreme Court to grant a petition asking the Justices to consider whether “in a patent-infringement suit, a court may consider after- arising technology to hold that the patent is invalid under § 112(a) of the Patent Act.” The case arises from a U.S. Court of Appeals for the Federal Circuit (CAFC) January 2025 precedential decision reversing a district court’s determination that certain claims of a patent for Novartis’ heart failure drug Entresto were invalid for lack of written description, and affirming a finding that the claims were not shown to be invalid for obviousness, lack of enablement, or indefiniteness.
A petition for certiorari is currently pending before the United States Supreme Court which raises serious concerns as to fundamental principles of patent law, especially relating to the enablement requirement of 35 U.S.C. §112. In the decision by the U.S. Court of Appeals for the Federal Circuit which gave rise to the petition in question, an “after-arising technology” exception was carved out from the requirement that a patent claim as construed must be enabled as to its full scope. The ruling did violence to other important rules, but it also has potential far-reaching consequences that have not been explored. It is essential that the Supreme Court grant certiorari to steer the law in the right direction.
In a precedential decision issued on June 11, 2025, the U.S. Court of Appeals for the Federal Circuit (CAFC) affirmed two Patent Trial and Appeal Board (PTAB) inter partes review (IPR) decisions invalidating Agilent Technologies’ patents related to chemically modified CRISPR guide RNAs (gRNAs).